SPE Capital has announced the sale of Amanys Pharma to Laprophan, aiming to create a diversified pharmaceutical group in Morocco, pending regulatory approvals.
Target Information
On November 11, 2023, SPE Capital, an independent private equity firm, announced the sale of Amanys Pharma to Laprophan, a leading pharmaceutical company in Morocco. This transaction is pending the necessary regulatory approvals. This marks the second successful exit for SPE AIF, a $260 million African-focused fund under the management of SPE Capital, which reached its final close in December 2020.
Amanys Pharma, established in 2011, has made a name for itself in the production of antibiotics for GlaxoSmithKline (GSK) and its own brand. The company also distributes medicines to the hospital sector, serving both its interests and those of various international laboratories.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Morocco
Morocco's pharmaceutical industry is one of the most advanced in North Africa, characterized by a mixture of local manufacturers and international firms. The sector has seen considerable growth due to strong government support aimed at promoting loca
Similar Deals
Consortium of leading Moroccan businesspersons → Polymedic
2025
Bambu Ventures → Lemonaid Health
2026
Laprophan
invested in
Amanys Pharma
in 2023
in a Buyout deal